NI
60
2
ORLY
57
3
CA
13
3
FDX
30
-9
VZ
32
-2
CSX
55
-2
NOV
52
3
BBY
43
3
APD
47
-2
PSA
51
5
HRB
54
2
KEY
33
-4
ROST
54
9
LMT
27
-2
OKE
65
4
PBI
60
17
HPE
38
-15
HP
36
3
DHI
45
2
CHRW
50
13
NI
60
2
ORLY
57
3
CA
13
3
FDX
30
-9
VZ
32
-2
CSX
55
-2
NOV
52
3
BBY
43
3
APD
47
-2
PSA
51
5
HRB
54
2
KEY
33
-4
ROST
54
9
LMT
27
-2
OKE
65
4
PBI
60
17
HPE
38
-15
HP
36
3
DHI
45
2
CHRW
50
13
Financhill
Back

Theravance Biopharma 10K Form

Sell
47

TBPH
Theravance Biopharma

Last Price:
8.23
Seasonality Move:
11.3%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TBPH News And Ratings

See the #1 stock for the next 7 days that we like better than TBPH

TBPH Financial Statistics

Sales & Book Value

Annual Sales: $57.42M
Cash Flow: $-4.45M
Price / Cash Flow: 0
Annual Sales: $3.96
Price / Book: 2.08

Profitability

EPS (TTM): -0.92000
Net Income (TTM): $-45.65M
Gross Margin: $71.86M
Return on Equity: -20.06%
Return on Assets: -11.56%

Theravance Biopharma Earnings Forecast

Key Theravance Biopharma Financial Ratios

  • The Gross Profit Margin over the past 9 years for TBPH is 100.00%.
  • The Selling, General & Administrative Expenses for TBPH have been equal to 122.07% of Gross Profit Margin.
  • The Research & Development expenses have been 70.74% of Revenue.
  • The Interest Expense is -4.26% of Operating Income.
  • The Net Earning history of TBPH is -96.11% of Total Revenues.
  • Per Share Earnings over the last 12 years have been positive in 5 years.

Theravance Biopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TBPH
CUSIP: G8807B
Website: theravance.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 5.2
Quick Ratio: 4.81

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 8.52

TBPH Technical Analysis vs Fundamental Analysis

Sell
47
Theravance Biopharma (TBPH) is a Sell

Is Theravance Biopharma a Buy or a Sell?